{"id":108380,"date":"2023-08-28T18:25:24","date_gmt":"2023-08-28T12:55:24","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=108380"},"modified":"2023-08-28T18:25:26","modified_gmt":"2023-08-28T12:55:26","slug":"venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/","title":{"rendered":"Venus Remedies Receives Approval for Anticoagulant in Saudi Arabia"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-825002423\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p><strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/VENUSREM\/consolidated\" target=\"_blank\" rel=\"noreferrer noopener\">Venus Remedies<\/a><\/strong> announced on Monday that it has received the marketing approval for Enoxaparin in pre-filled syringes in Saudi Arabia. The drug is an anticoagulant, i.e, it prevents blood clots. Enoxaparin plays a crucial role in addressing blood clot formation in patients suffering from deep-vein thrombosis, acute coronary syndrome, heart attacks and pulmonary embolism.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-250516999\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>Venus currently has an annual capacity for producing more than 50 lakh units of Enoxaparin, a widely used anticoagulant that prevents blood clots, at its robotic line. Cardiovascular diseases are a major health issue in Saudi Arabia, accounting for 145 deaths in every 1 lakh people, highlighting the urgent need to mitigate clot-related complications, the statement said.<\/p><p>The company stated this approval will help the company with its commitment to making and increasing impact in the MEA region and expand its presence there. So far, the company said it has sold more than 12 million units of drugs in the Saudi Arabian pharmaceutical market which was estimated to be worth USD 7.8 billion in 2021. The market is expected to grow to USD 13.1 billion by 2031 at a 10-year CAGR of 5.4%.<\/p><p>Venus Remedies engages in the development and marketing of pharmaceutical products in India and internationally. Venus closed green, up 3% on Monday, down from its day high of 5%. The company has a market cap of Rs. 314 crores and has a strong financial book, indicated by a Piotroski F score of 7.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-576119936\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><div class=\"trade-after-content\" id=\"trade-2485401261\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>Venus Remedies announced on Monday that it has received the marketing approval for Enoxaparin in pre-filled syringes in Saudi Arabia. The drug is an anticoagulant, i.e, it prevents blood clots. Enoxaparin plays a crucial role in addressing blood clot formation in patients suffering from deep-vein thrombosis, acute coronary syndrome, heart attacks and pulmonary embolism. Venus [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":49884,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1696,31],"tags":[],"class_list":["post-108380","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-corporate-action","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Venus Remedies Receives Approval for Anticoagulant in Saudi Arabia - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"Venus Remedies announced on Monday that it has received the marketing approval for Enoxaparin in pre-filled syringes in Saudi Arabia. The drug is an anticoagulant, i.e, it prevents blood clots. Enoxaparin plays a crucial role in addressing blood clot formation in patients suffering from deep-vein thrombosis, acute coronary syndrome, heart attacks and pulmonary embolism.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Venus Remedies Receives Approval for Anticoagulant in Saudi Arabia\" \/>\n<meta property=\"og:description\" content=\"Venus Remedies announced on Monday that it has received the marketing approval for Enoxaparin in pre-filled syringes in Saudi Arabia. The drug is an anticoagulant, i.e, it prevents blood clots. Enoxaparin plays a crucial role in addressing blood clot formation in patients suffering from deep-vein thrombosis, acute coronary syndrome, heart attacks and pulmonary embolism.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-28T12:55:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-28T12:55:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/\",\"url\":\"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/\",\"name\":\"Venus Remedies Receives Approval for Anticoagulant in Saudi Arabia - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"datePublished\":\"2023-08-28T12:55:24+00:00\",\"dateModified\":\"2023-08-28T12:55:26+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"Venus Remedies announced on Monday that it has received the marketing approval for Enoxaparin in pre-filled syringes in Saudi Arabia. The drug is an anticoagulant, i.e, it prevents blood clots. Enoxaparin plays a crucial role in addressing blood clot formation in patients suffering from deep-vein thrombosis, acute coronary syndrome, heart attacks and pulmonary embolism.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Venus Remedies Receives Approval for Anticoagulant in Saudi Arabia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Venus Remedies Receives Approval for Anticoagulant in Saudi Arabia - Trade Brains Features","description":"Venus Remedies announced on Monday that it has received the marketing approval for Enoxaparin in pre-filled syringes in Saudi Arabia. The drug is an anticoagulant, i.e, it prevents blood clots. Enoxaparin plays a crucial role in addressing blood clot formation in patients suffering from deep-vein thrombosis, acute coronary syndrome, heart attacks and pulmonary embolism.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/","og_locale":"en_US","og_type":"article","og_title":"Venus Remedies Receives Approval for Anticoagulant in Saudi Arabia","og_description":"Venus Remedies announced on Monday that it has received the marketing approval for Enoxaparin in pre-filled syringes in Saudi Arabia. The drug is an anticoagulant, i.e, it prevents blood clots. Enoxaparin plays a crucial role in addressing blood clot formation in patients suffering from deep-vein thrombosis, acute coronary syndrome, heart attacks and pulmonary embolism.","og_url":"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2023-08-28T12:55:24+00:00","article_modified_time":"2023-08-28T12:55:26+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/","url":"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/","name":"Venus Remedies Receives Approval for Anticoagulant in Saudi Arabia - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","datePublished":"2023-08-28T12:55:24+00:00","dateModified":"2023-08-28T12:55:26+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"Venus Remedies announced on Monday that it has received the marketing approval for Enoxaparin in pre-filled syringes in Saudi Arabia. The drug is an anticoagulant, i.e, it prevents blood clots. Enoxaparin plays a crucial role in addressing blood clot formation in patients suffering from deep-vein thrombosis, acute coronary syndrome, heart attacks and pulmonary embolism.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/venus-remedies-receives-approval-for-anticoagulant-in-saudi-arabia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Venus Remedies Receives Approval for Anticoagulant in Saudi Arabia"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/108380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=108380"}],"version-history":[{"count":3,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/108380\/revisions"}],"predecessor-version":[{"id":108390,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/108380\/revisions\/108390"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/49884"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=108380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=108380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=108380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}